WO2002097031A3 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents
Molecules utilisees a des fins diagnostiques et therapeutiques Download PDFInfo
- Publication number
- WO2002097031A3 WO2002097031A3 PCT/US2002/010056 US0210056W WO02097031A3 WO 2002097031 A3 WO2002097031 A3 WO 2002097031A3 US 0210056 W US0210056 W US 0210056W WO 02097031 A3 WO02097031 A3 WO 02097031A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dithp
- provides
- therapeutics
- diagnostics
- diagnostic assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002344208A AU2002344208A1 (en) | 2001-03-28 | 2002-03-27 | Molecules for diagnostics and therapeutics |
CA002442705A CA2442705A1 (fr) | 2001-03-28 | 2002-03-27 | Molecules utilisees a des fins diagnostiques et therapeutiques |
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27961901P | 2001-03-28 | 2001-03-28 | |
US60/279,619 | 2001-03-28 | ||
US28006801P | 2001-03-29 | 2001-03-29 | |
US28006701P | 2001-03-29 | 2001-03-29 | |
US60/280,067 | 2001-03-29 | ||
US60,280,068 | 2001-03-29 | ||
US29128001P | 2001-05-16 | 2001-05-16 | |
US60/291,280 | 2001-05-16 | ||
US29182901P | 2001-05-17 | 2001-05-17 | |
US29184901P | 2001-05-17 | 2001-05-17 | |
US60,291,829 | 2001-05-17 | ||
US60/291,849 | 2001-05-17 | ||
US29942801P | 2001-06-19 | 2001-06-19 | |
US60,299,428 | 2001-06-19 | ||
US30000101P | 2001-06-20 | 2001-06-20 | |
US29977601P | 2001-06-20 | 2001-06-20 | |
US60/300,001 | 2001-06-20 | ||
US60/299,776 | 2001-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002097031A2 WO2002097031A2 (fr) | 2002-12-05 |
WO2002097031A3 true WO2002097031A3 (fr) | 2005-05-12 |
Family
ID=27578771
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/010056 WO2002097031A2 (fr) | 2001-03-28 | 2002-03-27 | Molecules utilisees a des fins diagnostiques et therapeutiques |
PCT/US2002/009944 WO2002079449A2 (fr) | 2001-03-28 | 2002-03-27 | Molecules permettant de detecter et de traiter des maladies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/009944 WO2002079449A2 (fr) | 2001-03-28 | 2002-03-27 | Molecules permettant de detecter et de traiter des maladies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1383894A2 (fr) |
AU (2) | AU2002338265A1 (fr) |
CA (2) | CA2442705A1 (fr) |
WO (2) | WO2002097031A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394330B2 (en) | 2012-03-21 | 2016-07-19 | Alios Biopharma, Inc. | Solid forms of a thiophosphoramidate nucleotide prodrug |
CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244827B2 (en) | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
EP1434783A4 (fr) * | 2001-03-16 | 2006-06-07 | Lilly Co Eli | Proteines de mammiferes lp et reactifs associes |
ATE364690T1 (de) | 2001-11-09 | 2007-07-15 | Proteologics Inc | Posh nukleinsäure, polypeptide und darauf bezogene verfahren |
US8753822B2 (en) * | 2001-12-04 | 2014-06-17 | Wayne State University | Neoepitope detection of disease using protein arrays |
US8450067B2 (en) * | 2002-05-28 | 2013-05-28 | Omrix Biopharmaceuticals Inc. | Method for obtaining anti-idiotype antibodies |
US20040053304A1 (en) | 2002-06-05 | 2004-03-18 | Case Western Reserve University | Methods and compositions for detecting cancers |
WO2004016733A2 (fr) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers |
TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
EP1507006A4 (fr) * | 2002-10-11 | 2006-05-24 | Yamanouchi Pharma Co Ltd | Procede de criblage d'un medicament contre l'insuffisance renale |
EP2311870A1 (fr) * | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
US7396666B2 (en) * | 2002-12-27 | 2008-07-08 | National Institute Of Advanced Industrial Science And Technology | Glycosyltransferase, nucleic acid encoding the glycosyltransferase and method of testing canceration using the nucleic acid |
GB0315827D0 (en) * | 2003-07-05 | 2003-08-13 | Imp College Innovations Ltd | Methods |
US20080274975A1 (en) * | 2004-04-12 | 2008-11-06 | The Trustees Of Columbia University In The City Of New Yourk | Methods and Compositions for Inhibiting Abad/Abeta Protein Interaction |
EP1627922A1 (fr) * | 2004-08-18 | 2006-02-22 | Sanofi-Aventis Deutschland GmbH | Méthode de sélection d'agonistes et d'antagonistes du transporteur de carnitine et son utilisation |
GB0423126D0 (en) * | 2004-10-18 | 2004-11-17 | Ares Trading Sa | Protein |
US7727725B2 (en) * | 2006-04-27 | 2010-06-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
WO2008070090A2 (fr) | 2006-12-05 | 2008-06-12 | Oncomed Pharmaceuticals, Inc. | Compositions et procédés pour diagnostiquer et traiter un cancer |
US20110250218A1 (en) | 2008-10-29 | 2011-10-13 | Fong Lawrence H | Disease-Associated Antigens and Methods of Use Thereof |
AU2009313808B2 (en) | 2008-11-14 | 2013-05-16 | Gen-Probe Incorporated | Compositions, kits and methods for detection of campylobacter nucleic acid |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CN107098958B (zh) | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
PE20140608A1 (es) | 2010-09-22 | 2014-06-12 | Alios Biopharma Inc | Analogos de nucleotidos sustituidos |
EP2794630A4 (fr) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Analogues de nucléotide phosphorothioate substitués |
WO2013142157A1 (fr) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Combinaisons pharmaceutiques comprenant un analogue thionucléotidique |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CA2884704C (fr) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Modulateurs vista de diagnostic et de traitement de cancer |
MX369173B (es) | 2013-12-24 | 2019-10-30 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista. |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
CN107073109B (zh) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Vista激动剂和拮抗剂抑制或增强体液免疫的用途 |
WO2016090347A1 (fr) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification de vsig8 en tant que récepteur putatif de vista et son utilisation pour produire des modulateurs de vista/vsig8 |
BR112017027870A2 (pt) | 2015-06-24 | 2018-08-28 | Janssen Pharmaceutica Nv | anticorpos e fragmentos anti-vista |
BR112018016461A2 (pt) | 2016-02-12 | 2019-10-01 | Janssen Pharmaceutica Nv | anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos |
MX2018012469A (es) | 2016-04-15 | 2019-07-04 | Immunext Inc | Anticuerpos vista antihumanos y uso de los mismos. |
WO2020006108A2 (fr) * | 2018-06-26 | 2020-01-02 | Duke University | Récepteurs odorants synthétiques |
CN110714017B (zh) * | 2019-11-06 | 2023-09-01 | 河南师范大学 | 锦鲤ptps基因、编码蛋白及应用 |
CN114317732B (zh) * | 2021-04-08 | 2023-08-18 | 博尔诚(北京)科技有限公司 | 用于肺癌筛查的组合物及其应用 |
-
2002
- 2002-03-27 WO PCT/US2002/010056 patent/WO2002097031A2/fr not_active Application Discontinuation
- 2002-03-27 AU AU2002338265A patent/AU2002338265A1/en not_active Abandoned
- 2002-03-27 WO PCT/US2002/009944 patent/WO2002079449A2/fr not_active Application Discontinuation
- 2002-03-27 EP EP02744104A patent/EP1383894A2/fr not_active Ceased
- 2002-03-27 CA CA002442705A patent/CA2442705A1/fr not_active Abandoned
- 2002-03-27 AU AU2002344208A patent/AU2002344208A1/en not_active Abandoned
- 2002-03-27 CA CA002447183A patent/CA2447183A1/fr not_active Abandoned
Non-Patent Citations (4)
Title |
---|
DATABASE GENBANK [online] 12 August 2000 (2000-08-12), BIRREN B. ET AL., XP002985580, Database accession no. AC026828 * |
DATABASE GENBANK [online] 12 May 1998 (1998-05-12), LEE G.H. ET AL., XP002985581, Database accession no. OAU94889 * |
DATABASE GENBANK [online] 12 May 2000 (2000-05-12), BIRREN B. ET AL., XP002985579, Database accession no. AC036206 * |
DATABASE GENBANK [online] 5 August 1998 (1998-08-05), DAVOLI R. ET AL., XP002985582, Database accession no. SSGAPDH * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394330B2 (en) | 2012-03-21 | 2016-07-19 | Alios Biopharma, Inc. | Solid forms of a thiophosphoramidate nucleotide prodrug |
CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
Also Published As
Publication number | Publication date |
---|---|
AU2002338265A1 (en) | 2002-10-15 |
CA2447183A1 (fr) | 2002-10-10 |
CA2442705A1 (fr) | 2002-12-05 |
WO2002097031A2 (fr) | 2002-12-05 |
AU2002344208A1 (en) | 2002-12-09 |
WO2002079449A3 (fr) | 2003-03-20 |
AU2002344208A8 (en) | 2005-11-17 |
WO2002079449A2 (fr) | 2002-10-10 |
EP1383894A2 (fr) | 2004-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002097031A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2004023973A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2000073509A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2002083876A3 (fr) | Molecules secretoires | |
WO2005056600A3 (fr) | Anticorps monoclonaux se liant ou neutralisant le virus de la dengue | |
WO2004037999A3 (fr) | Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees | |
WO2005069854A3 (fr) | Procedes et materiaux ayant trait a de nouveaux polypeptides et polynucleotides contenant le domaine c1q | |
WO2003020894A3 (fr) | Facteur de transcription lie a l'insuline et utilisations de celui-ci | |
WO2002046228A3 (fr) | Recepteur de la toxine du b. anthracis | |
WO2001068859A3 (fr) | Molecules du type recepteur de l'interleukine 17 et leur utilisation | |
WO2001068705A3 (fr) | Molecules du type recepteur de l'interleukine 17 et leurs utilisations | |
WO2002099080A3 (fr) | Methodes de clonage d'adn, a faible pourcentage de clones negatifs, a l'aide d'oligonucleotides longs | |
WO2003062376A3 (fr) | Molécules pour le diagnostic et la thérapeutique | |
WO2002020756A3 (fr) | Molécules sécrétoires | |
WO2002040715A3 (fr) | Molecules permettant la detection et le traitement de maladies | |
WO2001062927A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2003062385A3 (fr) | Molecules secretoires | |
WO2001062922A3 (fr) | Molecules destinees a la detection et au traitement de maladies | |
WO2002020754A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2002055738A3 (fr) | Molecules pour la detection et le traitement de maladies | |
WO2001062918A3 (fr) | Molecules secretoires | |
WO2002079473A3 (fr) | Molecules utilisees a des fins diagnostiques et therapeutiques | |
WO2001021836A3 (fr) | Molecules pour le diagnostic et la therapeutique | |
WO2000075298A3 (fr) | Molecules pour la detection et le traitement de maladies | |
WO2002057304A3 (fr) | Molecules secretrices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002751955 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2442705 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002751955 Country of ref document: EP |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |